Research Funding Completed
The following are some of the recent research that have significant potential to either improving time diagnosis or enhancing a patient’s quality of life.
SINGLE CELL ATLAS DR. IVAN ROSAS, Pulmonary, Critical care and Sleep Medicine, Baylor College of Medicine. DR. NAFTALI KAMINSKI, Pulmonary, Critical care and Sleep Medicine, Yale University School of Medicine
Our partnership with the Rosas and Kaminski labs on the Pulmonary Fibrosis Cell Atlas generated valuable data and insights that are now available to all investigators advancing treatments for PF. To develop effective therapies for PF, we need to understand all of the cellular changes happening in the human lung as fibrosis develops. Specifically we need to define the changes in resident and infiltrating cells, identifying emergent novel and ectopic cell types, and map the altered cell-cell communications as this would allow developing interventions that will stop or reverse fibrosis. The Rosas and Kaminski labs used state-of-the-art technologies to create viable single cell lung suspensions from IPF tissues, and generated high throughput profiles of all cells in the IPF lung at the single cell resolution using single cell RNA sequencing. Using advanced computational methods, the researchers identified evidence for novel aberrant and ectopic cell populations in the IPF lung and generated a catalogue of all the phenotypic changes in all lung cells in the disease. This resulted in the creation of the IPF Cell Atlas (www.IPFCellAtlas.com) data dissemination portal that allows free mining and exploration of the data to accelerate the development of novel therapies in PF.Learn More
CleanUP STUDY (Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Ideopathic Pulmonary Fibrosis) DR. FERNANDO MARTINEZ WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
The CleanUP IPF study is part of the Pulmonary Trials Cooperative (PTC) established by the National Heart, Lung, and Blood Institute (NHLBI). The PTC is a collaborative network of investigators and clinical centers that are conducting research and developing novel therapies to improve the outcomes of patients with chronic pulmonary diseases. Past research indicates that IPF patients treated with the antimicrobials co-trimoxazole (Bactrim) or doxycycline may have improved clinical outcomes. The CleanUP IPF trial is designed to confirm whether antimicrobial therapy plus standard of care will improve clinical outcomes such as the length of time to a rehospitalization and mortality in patients with PF. The study work is being conducted with over 500 subjects at 31 research institutions across teh U.S. and includes a pragmatic randomized trial design and collection of data that will be used to develop future personalized therapies.
New Drug Development Dr. Philip Low, Purdue University
The Low Lab at Purdue University is working to identify and validate novel therapies for pulmonary fibrosis. The lab has unique experience in the development of targeted molecules called small molecule drug conjugates (SMDC), which deliver compounds directly to the cells that develop and perpetuate IPF. Developing these compounds requires a specific small molecule, an optimized linker, and a ligand specific for the cells being targeted. Finding the proper combination of these three parts is challenging, but with its proven expertise, the Low Lab, a global leader in targeted therapies, continues to drive this development forward.